Trademark: FAST FOUNDATION FOR ANGELMAN SYNDROME THERAPEUTICS
Put your brand on the blockchain and timestamp its proof of existence at wikitrademarks.io
Track updates on FAST FOUNDATION FOR ANGELMAN SYNDROME THERAPEUTICS
Mark Identification
FAST FOUNDATION FOR ANGELMAN SYNDROME THERAPEUTICS
Click here to search for trademarks similar to FAST FOUNDATION FOR ANGELMAN SYNDROME THERAPEUTICS
Proof of use for FAST FOUNDATION FOR ANGELMAN SYNDROME THERAPEUTICS
We do not have any records of a proof of use for FAST FOUNDATION FOR ANGELMAN SYNDROME THERAPEUTICS at this moment.
Click here to add a proof of use for FAST FOUNDATION FOR ANGELMAN SYNDROME THERAPEUTICS
Possible trademark infringements of FAST FOUNDATION FOR ANGELMAN SYNDROME THERAPEUTICS
Basic Information about FAST FOUNDATION FOR ANGELMAN SYNDROME THERAPEUTICS
- Serial Number
- 88416631
- Filing Date
- 06 May 2019
- Registration Number
- 5936233
- Registration Date
- 17 Dec 2019
- Mark Drawing Code
- 4
Classifications
Declare the trademark use of FAST FOUNDATION FOR ANGELMAN SYNDROME THERAPEUTICS on the blockchain with WikiTrademarks.io.
- First use of FAST FOUNDATION FOR ANGELMAN SYNDROME THERAPEUTICS anywhere
- FAST FOUNDATION FOR ANGELMAN SYNDROME THERAPEUTICS was first used on 28 Aug 2008 for the primary classification of goods and services, international, 036 (Insurance and financial)
- First use in commerce
- There is no first use of this trademark in commerce detected yet.
- Status Code
- 6
- International Code
- 036
- US Codes
- 100; 101; 102
Who owns FAST FOUNDATION FOR ANGELMAN SYNDROME THERAPEUTICS?
1. Foundation for Angelman Syndrome Therapeutics Downers Grove IL
2. Foundation for Angelman Syndrome Therapeutics Downers Grove IL
3. Foundation for Angelman Syndrome Therapeutics Downers Grove IL
Correspondent
- Hemant Gupta Epstein Becker & Green, P.C.
- 1222 Demonbreun Street, Suite 1400
- Nashville, MD 37203
- United States
Put your brand on the blockchain and timestamp its proof of existence at Wikitrademarks.io
Track updates on FAST FOUNDATION FOR ANGELMAN SYNDROME THERAPEUTICS